Highlights Gilead Sciences, Inc.

Equities

GILD

US3755581036

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
64.7 ^USD	+1.33%		+0.67%	-20.13%

Jun. 06	Gilead Says Bulevirtide With PegIFN Data 'Superior' to Bulevirtide Monotherapy; Achieves 46% Rate of Undetectable HDV RNA	MT
Jun. 06	Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Gilead Says Bulevirtide With PegIFN Data 'Superior' to Bulevirtide Monotherapy; Achieves 46% Rate of Undetectable HDV RNA	Jun. 06	MT
Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study	Jun. 06	CI
Gilead Sciences Says Investigational Chronic Liver Disease Drug Shows 'Sustained Efficacy' in Long-Term Trial	Jun. 05	MT
Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis, A Rare, Chronic Inflammatory Liver Disease	Jun. 05	CI
Sector Update: Health Care Stocks Rise Late Afternoon	Jun. 04	MT
Sector Update: Health Care Stocks Rise Tuesday Afternoon	Jun. 04	MT
Gilead Sciences Agrees to $40 Million Settlement of Federal TDF Lawsuit	Jun. 04	MT
Gilead Sciences Unit Says Tecartus Improves Overall Survival in Leukemia, Yescarta Well-Tolerated in Lymphoma	Jun. 03	MT
Kite?S Tecartus® Demonstrates Sustained Overall Survival in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia	Jun. 03	CI
Kite Announces Data from A Pilot Study in Collaboration with Dana-Farber Cancer Institute	Jun. 03	CI
Gilead Sciences, Arcus Biosciences's Colorectal Cancer Combination Therapy Shows Promise	Jun. 03	MT
Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer	Jun. 02	CI
Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as A First-Line Treatment for Upper GI Cancers	Jun. 01	CI
Gilead's Trodelvy fails bladder cancer trial, modestly extends lung cancer survival	May. 31	RE
Gilead Sciences Says Phase 3 Study Shows Trodelvy Cut Risk of Death by 16% in Non-Small Cell Lung Cancer Patients	May. 31	MT
Gilead Sciences, Inc. Announces Detailed Results from the Phase 3 Evoke-01 Study	May. 31	CI
Gilead Sciences Says Phase 3 Trial in Urothelial Cancer Misses Primary Target	May. 30	MT
Gilead's Trodelvy fails to meet main goal in late-stage study	May. 30	RE
Gilead Sciences, Inc. Provides Update on Phase 3 Tropics-04 Study	May. 30	CI
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program	May. 09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Gilead Sciences, Inc.

Equities

GILD

US3755581036

Highlights

Filters